
Heart Drug Protects Child Cancer Survivors for 15+ Years
A groundbreaking study of 900 childhood cancer survivors shows that dexrazoxane dramatically reduces heart damage from chemotherapy for over 15 years after treatment ends. The discovery could mean fewer heart tests and more peace of mind for young cancer survivors and their families.

















